We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > Psychedelics

Psychedelics

Psilocybin Helps Treat Depression in Phase 2 Trial

The researchers say their findings add to the growing body of evidence that psilocybin can be used in a clinical setting to treat depression.

Read More

Cannabis Use at All-Time-High in US, Finds NIH Survey

Cannabis and hallucinogens are more popular than ever in the US, according to an ongoing National Institutes of Health (NIH) survey.

Read More

Psilocybin Is Safe to Give to Anorexic Patients, Trial Finds

Researchers gave the ‘magic mushroom’ drug to ten participants with anorexia, who then received follow-up psychological support.

Read More

FDA Releases Draft Guidance For Psychedelic Drugs Research

Comments from the public and relevant professionals are welcome and will be accepted until August 25.

Read More

What Are Synthetic Psychedelics?

In a panel discussion last year, Analytical Cannabis brought together five experts on psychedelics to discuss these new psychedelic NCEs, and to provide new perspectives on the future of the psychedelic drug development landscape.

Read More

Uncovering the Mechanisms of Action of Psychedelic Drugs

Psychedelics can be classified into three main groups, but how does each type affect the brain?

Read More

No Differences Between Equivalent Doses of LSD, Mescaline, and Psilocybin, Study Finds

There are no significant differences in the effects of LSD, mescaline, or psilocybin when given at equivalent doses, according to a new study.

Read More

Ketamine Treats Pain By Treating Depression, Study Suggests

The study involved over 300 chronic pain patients who received more than one infusion of ketamine over several months. All participants reported pain relief; those with depression experienced “more robust” relief.

Read More

Psilocybin Temporarily Improves Man’s Color Blindness, Report Claims

The report, published in the journal Drug Science, Policy and Law, details the experiences of a 35-year-old man who had been diagnosed with a mild case of red-green color blindness five years earlier.

Read More

 
Advertisement